Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma
jRCT2080222561Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS) (2 arms), sponsored by Kyowa Kirin. Started Jul 2014; status: completed.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on jRCT2080222561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222561.